Aceto Expands Biopharmaceutical and Cell Culture Reagent Portfolio to Meet Customer Demand
Using the capabilities of Pharma Waldhof, one of Aceto’s facilities in Düsseldorf, Germany, the company plans to provide customers with access to raw materials, tested products for pharmaceutical cell culture applications, and cell culture media ingredients.
Aceto, a virtual manufacturer of specialty materials for life sciences and advanced technology end markets, announced on March 15, 2021 that it has introduced an expanded portfolio for biopharmaceutical and cell culture reagent manufacturers.
Using the capabilities of Pharma Waldhof, one of Aceto’s facilities in Düsseldorf, Germany, the company plans to provide customers with access to raw materials including nucleotides, nucleosides, and bio-buffers, along with tested products for pharmaceutical cell culture applications, such as ingredients for hybridoma and Chinese hamster ovary cell culture media used in biopharmaceutical and vaccine manufacturing, Aceto said in a company press release. The expansion will also supply customers with cell culture media ingredients such as amino acids and vitamins.
“Aceto is active in new product development and advanced manufacturing techniques to position the company as a preferred supplier to the highly regulated biopharma and cell culture industries” said Gilles Cottier, CEO, Aceto, in the press release. “Using the extensive Aceto network worldwide makes it easier for customers to access their robust portfolio of products, while working with a company that is vested in its customers’ success.”
Source: Aceto
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
